In adults with IBS-D

Well-established safety profile1

Unlike other prescription IBS-D treatments, XIFAXAN is:

  • NOT a controlled substance1
  • NOT contraindicated in patients without a gallbladder1
  • No association of pancreatitis observed in patients taking XIFAXAN in clinical trials1

Side effects at rates similar to placebo1

ALT = alanine aminotransferase

NA = not available

*Most of the events of ALT increased were due to transient increases that resolved over time and were not temporally associated with study drug treatment.2

  • Constipation was observed in only 0.5% of XIFAXAN patients2
  • Did not cause any clinically relevant antibiotic resistance after 1 to 3 treatment cycles3
    • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued1

Dosing is convenient, not continuous1

  • Just 2 weeks of treatment, not continuous daily prescription medication1
  • One 550 mg tablet 3 times a day with or without food1
  • Patients who experience recurrence can be retreated up to two times1

Find access and savings information

IBS-D = irritable bowel syndrome with diarrhea

†The ICD-10 Codes and all other patient access related information are provided for informational purposes only. It is the treating physician’s responsibility to determine the proper diagnosis, treatment and applicable ICD-10 Code. Salix Pharmaceuticals does not guarantee coverage or reimbursement for the product.

In the know:
Ask patients to track IBS-D symptoms

View resource
 

See how XIFAXAN is
believed to work

See the science
 

Look up insurance coverage

Search now
 
SEE MORE
INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.